
In a U-turn on its previous guidance NICE is now recommending that the £330,000 rare disease drug Soliris should be …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

